Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) today and set a price target of $38.00. The company’s shares closed last Friday at $15.59.
According to TipRanks.com, Syed is a 1-star analyst with an average return of -3.8% and a 51.4% success rate. Syed covers the Healthcare sector, focusing on stocks such as Assembly Biosciences, Coherus Biosciences, and Unity Biotechnology.
Currently, the analyst consensus on Atara Biotherapeutics is a Strong Buy with an average price target of $33.25, an 119.8% upside from current levels. In a report issued on May 7, Canaccord Genuity also maintained a Buy rating on the stock with a $70.00 price target.
The company has a one-year high of $24.75 and a one-year low of $4.52. Currently, Atara Biotherapeutics has an average volume of 1.04M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.